Malaria Clinical Trial
Official title:
Paracetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial
Blackwater fever, characterized by intravascular haemolysis and hemoglobinuria, is an
important cause of renal impairment and mortality in severe malaria caused by Plasmodium
falciparum. The largest malaria clinical trials report blackwater incidences of 5-7% in Asian
adults and 4% in African children with severe malaria treated with artesunate or quinine. The
prevalence of blackwater fever in Chittagong, Bangladesh is 15% with associated rates of
renal failure and mortality of 42.9% and 14.2% respectively.
The fundamental characteristic of blackwater fever is the presence of intravascular hemolysis
of both infected and uninfected erythrocytes and release of free haemoglobin. The cytotoxic
free haemoglobin present can cause severe oxidative damage as a result of haem redox cycling
yielding ferric and ferryl heme, which generate radical species that induce lipid
peroxidation and subsequent production of F2-isoprostanes (F2-IsoPs). Evidence suggests that
F2-IsoPs generated by the hemoprotein-catalyzed oxidation of lipids are responsible for the
oxidative damage and vasoconstriction associated with renal injury in haemolytic disorders
and rhabdomyolysis.
A novel mechanism of paracetamol was recently demonstrated, showing that paracetamol is a
potent inhibitor of hemoprotein-catalyzed lipid peroxidation by reducing ferryl heme to its
less toxic ferric state and quenching globin radicals. In a recent proof of concept trial,
paracetamol at therapeutic levels was shown to significantly decrease oxidant kidney injury,
improve renal function and reduce renal damage by inhibiting the hemoprotein-catalyzed lipid
peroxidation in a rat model of rhabdomyolysis-induced renal injury. Since adults with severe
malaria demonstrate increased concentrations of cell-free haemoglobin, and urinary F2-IsoPs,
the investigators hypothesize that this novel inhibitory mechanism of paracetamol may provide
renal protection in this population by reducing the hemoprotein-induced lipid peroxidation.
As there is currently no consensus that exists concerning adequate medical treatment for
blackwater fever, the potential application of this safe and extensively used drug would be
of great benefit.
Mortality in severe malaria remains ~15% despite the best available parasiticidal
antimalarial therapy, intravenous artesunate. Adjunctive therapies in combination with
anti-parasitic drugs have the potential to improve outcomes. However, currently there are no
proven adjunctive therapies for the treatment of severe malaria, which can improve
case-fatality when used in combination with anti-parasitic drugs. This research proposal
focuses on exploring if paracetamol prevents renal dysfunction caused by free haemoglobin
induced oxidative damage in severe malaria.
Blackwater fever epidemiology As early as the 1800s, blackwater fever complicating severe
malaria caused by Plasmodium falciparum was recognized as an important cause of morbidity and
mortality, with a 25-30% mean mortality rate. The etiology and pathogenesis is poorly
understood but it is characterized by massive intravascular haemolysis and passage of black
or red urine, which can lead to renal impairment and death. This manifestation was linked to
quinine therapy as its occurrence nearly disappeared during the chloroquine era from 1950 to
1980. Since 1990, the resurgence in the number of cases noted in both malaria-free and
malarious areas in non-immune and immune individuals has generated renewed interest into this
manifestation of severe malaria. The largest malaria clinical trials report blackwater fever
incidences of 7% and 4% in Asian adult patients with severe malaria treated with artesunate
and quinine, respectively and 4% in African children treated with either drug. The prevalence
of blackwater fever in Chittagong, Bangladesh was recently determined in a pilot study to be
15% with associated renal failure and mortality rates of 42.9% and 14.2% respectively.
Blackwater fever pathogenesis Although the exact mechanism linking falciparum malaria and
blackwater fever is uncertain, numerous explanations have been suggested. It has been
proposed to occur in 4 specific circumstances: (1) in case patients with G6PD deficiency with
or without malaria who take oxidant drugs (primaquine) (2) in case patients with G6PD
deficiency and malaria untreated and treated with quinine (3) when patients (normal G6PD)
with severe malaria are treated with quinine (4) when people exposed to malaria self-medicate
with quinine or related amino-alcohol drugs. However, new circumstances of blackwater fever
have emerged, occurring in patients with normal G6PD levels with severe malaria who have
received artesunate rather than quinine.
Role of oxidative stress and free haem The fundamental characteristic of blackwater fever is
the presence of massive haemolysis of both infected and uninfected erythrocytes and release
of free haemoglobin. The free haem is highly cytotoxic, and an important scavenger of nitric
oxide, promoting endothelial damage and is proposed to be involved in the pathogenesis of
renal injury and cerebral malaria. When the degree of intravascular haemolysis exceeds the
capacity of plasma haptoglobin to bind the haemoglobin released from red blood cells, free
haemoglobin is then filtered by the glomeruli and enters the renal tubules. In a series of
renal biopsies, fine and coarse haemoglobin granules are present in the proximal tubules,
while haemoglobin casts and granular casts predominate in the distal and collecting tubules
in patients with blackwater fever and intravascular haemolysis. This classic theory of renal
damage by tubular precipitation is challenged by recent findings of reversing oxidative
properties of free haem can prevent renal damage. The free haemoglobin present is pathogenic
as the ferrous haem can be oxidized to the ferric state (FeIII) subsequently conferring
peroxidase activity to the haemoglobin. Consequently, the haemoglobin can reduce
hydroperoxides, such as hydrogen peroxide (H2O2) and lipid hydroperoxides, which generate the
ferryl state (FeIV=O) of haemoglobin and a globin protein radical.
Haem Fe(III) protein + H2O2 --> haem [Fe(IV)=O] protein• + H+ + H2O The ferryl haem and
protein radical can then generate lipid radicals by oxidation of free and
phospholipid-esterified unsaturated fatty acids. The arachidonic side chains of membrane
phospholipids are particularly vulnerable to this free radical-mediated damage in the complex
cascade of lipid oxidation leading to the generation of F2-isoprostanes (F2-IsoPs) and
isofurans (IsoFs). Evidence suggests that F2-isoPs generated by the haemoprotein-catalyzed
oxidation of lipids are responsible for the oxidative damage and vasoconstriction associated
with renal injury in the setting of hemolytic disorders and rhabdomyolysis.
Paracetamol and oxidative stress A novel mechanism of paracetamol was recently demonstrated,
showing that paracetamol acts as a potent inhibitor of haemoprotein-catalyzed lipid
peroxidation by reducing ferryl haem to its less toxic ferric state and quenching globin
radicals. This effect is enhanced 14-fold in an acidic milieu. In a recent proof of concept
trial, paracetamol at therapeutic levels was shown to significantly decrease oxidant injury
in the kidney, improve renal function and reduce renal damage by inhibiting the
haemoprotein-catalyzed lipid peroxidation, mediated by redox cycling of the haem moiety of
myoglobin, in a rat model of rhabdomyolysis-induced renal injury.
Rationale Since adults with severe malaria and blackwater fever associated with haemolysis
demonstrate increased concentrations of cell-free haemoglobin, severe acidosis and urinary
F2-IsoPs, the investigators hypothesize that this novel inhibitory mechanism of paracetamol
may provide renal protection in this population by reducing the haemoprotein-induced lipid
peroxidation. As there is currently no consensus that exists concerning adequate medical
treatment for blackwater fever, the potential application of this safe and extensively used
drug would be of great benefit.
Proposed activities The main activity proposed is a randomised open label controlled study of
paracetamol in patients with severe falciparum malaria to assess its modulating effect on
renal function and oxidative stress.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |